[1]申清云,高　大.老年急性髓系白血病的治疗方法研究进展[J].新乡医学院学报,2019,36(1):096-100.[doi:10.7683/xxyxyxb.2019.01.022]
点击复制

老年急性髓系白血病的治疗方法研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
36
期数:
2019年1
页码:
096-100
栏目:
综述
出版日期:
2019-01-05

文章信息/Info

作者:
申清云1; 高　大2
（1.内蒙古医科大学研究生学院，内蒙古　呼和浩特　010000；2.内蒙古医科大学附属医院血液科，内蒙古　呼和浩特　010000）
关键词:
急性髓系白血病; 老年患者; 治疗
分类号:
R733.71
DOI:
10.7683/xxyxyxb.2019.01.022
文献标志码:
A
摘要:
急性髓系白血病（AML）是一种异质性的血液系统恶性肿瘤，其发病率在老年人群中呈上升趋势，老年AML患者的治疗选择有限，即使获得初步缓解，预后也较差。随着医疗水平的不断提高，老年AML的治疗方法也逐渐多样化，更多新的药物应用于临床。本文就当前老年AML患者的临床特征及治疗方法作一综述。

参考文献/References:

［1］　JULIUSSON G，LAZAREVIC V，HRSTEDT A S，et al.Acute myeloid leukemia in the real world：why population-based registries are needed［J］.Blood，2012，119（17）：3890-3899.
［2］　SCHNEGGKAUFMANN A，FELLER A，BALDOMERO H，et al.Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013［J］.Cancer Epidemiolo，2018，52（5）：55-62.
［3］　黄昊，刘丽娜，刘玉章，等，改良CAG方案治疗难治复发性急性淋巴细胞白血病的疗效观察［J］.中华血液学杂志，2016，37（4）：340-342.
［4］　WEBSTER J A，PRATZ K W.Acute myeloid leukemia in the elderly：therapeutic options and choice［J］.Leuk Lymphoma，2018，59（2）：274-283.
［5］　JULIUSSON G，ANTUNOVIC P，DEROLF A，et al.Age and acute myeloid leukemia：real world data on decision to treat and outcomes from the swedish acute leukemia registry［J］.Blood，2009，113（18）：4179-4187.
［6］　YOSHIZATO T，NANNYA Y，ATSUTA Y，et al.Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia：impact on outcome of stem cell transplantation［J］.Blood，2017，129（17）：2347-2358.
［7］　ZHAO X L，LIU K Q，LIN D，et al.Characteristics of karyotypes and gene mutations for elder acute myeloid leukemia［J］.Exp Hematol，2015，23（2）：300-305.
［8］　YI J H，PARK S，KIM J H，et al.A multicenter，retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine［J］.Oncotarget，2018，9（5）：6607-6614.
［9］　SCHNEIDER F，HOSTER E，SCHNEIDER S，et al.Age-dependentfrequencies of NPM1 mutations and FLT3-ITDin patientswith normal karyotypeAML（NK-AML）［J］.Ann Hematol，2012，91（1）：9-18.
［10］　MAN C H，FUNG T K，HO C，et al.Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia：favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation［J］.Blood，2012，119（22）：5133-5143.
［11］　BODDU P C，KANTARJIAN H M，RAVANDI F，et al.Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach［J］.Cancer，2017，123（16）：3050-3060.
［12］　LEITH C P，KOPECKY K J，GODWIN J，et al.Acute myeloid leukemia in the elderly：assessment of multidrug resistance （MDR1） and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy.asouthwest oncology group study［J］.Blood，1997，89（9）：3323-3329.
［13］　KANTARJIAN H,O′BRIEN S.Questions regarding frontline therapy of acute Myeloid leukemia［J］.Cancer，2010，116(21):4896-4901.
［14］　ROBOZ G J.Novel approaches to the treatment of acute myeloid leukemia［J］.Hematology Am Soc Hematol Educ Program，2011，2011 （1）：43-50.
［15］　LEE J H，KIM H，JOO Y D，et al.Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acutemyeloid leukemia［J］.J Clin Oncol，2017，35（24）：2754-2763.
［16］　KIM M，KIM C，CHOI Y S，et al.Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential：implication to age-associated bone diseases and defects［J］.Mech Ageing Dev，2012，133（5）：215-225.
［17］　KANTARJIAN H，RAVANDI F，O′BRIEN S，et al.Intensive chemotherapydoes not benefit most older patients （age 70 years or older） with acute myeloid leukemia［J］.Blood，2010，116（22）：4422-4429.
［18］　O′DONNELL M R，ABBOUD C N，ALTMAN J，et al.NCCN clinical practice guidelines acute myeloid leukemia［J］.J Natl Compr Canc Netw，2017，15（7）：926-957.
［19］　BODDU P，KANTARJIAN H M，GARCIA-MANERO G，et al.Treated secondary acute myeloid leukemia：a distinct high-risk subset of AML with adverse prognosis［J］.Blood Adv，2017，1（19）：1312-1323.
［20］　LI J，CHEN Y，ZHU Y，et al.Efficacy and safety of decitabine in combination with G-CSF，low-does cytarbine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia［J］.Oncotarget，2015，6（8）：6448-6458.
［21］　赵冰冰，朱正，许彭鹏，等.老年急性髓细胞白血病非遗传学预后因素分析［J］.中华血液学杂志，2013，34（1）：3-7.
［22］　CHEN C，XU W，YANG J.Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia［J］.Leuk Lymphoma，2015，56（1）：141-146.
［23］　NIETO M，DEMOLIS P，BéHANZIN E，et al.The european medicines agency review of decitabine（dacogen） for the treatment of adult patients with acute myeloid leukemia：summary of the scientific assessment of the committee for medicinal products for human use［J］.Oncologist，2016，21（6）：692-700.
［24］　PARK H，CHO H，LEE J，et al.Treatment choice of decitabine versus conventional chemotherapy for the treatment of elderly patients with newly diagnosed acute myeloid leukemia［J］.Blood，2015，126（23）：4922.
［25］　GRISHINA O，SCHMOOR C，DHNER K，et al.Decider：prospective randomized multicenter phase Ⅱ trial of low-dose decitabine （DAC） administered alone or in combination with the histone deacetylase inhibitor valproic acid （VPA） and all-trans retinoic acid （ATRA） in patients >60 years with acutemyeloid leukemia who are ineligible for induction chemotherapy［J］.BMC Cancer，2015，15（1）：430-438.
［26］　朱雨，钱思轩，李建勇.《地西他滨治疗老年初诊急性髓系白血病的多中心、开放性、三期临床试验（注册试验DACO-016）》 解读［J］.中华血液学杂志，2013，34（1）：83-85.
［27］　VALDEZ B C，LI Y，MURRAY D，et al.Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin，acetylates DNA repair proteins，down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells［J］.Oncotarget，2018，9（3）：3908-3921.
［28］　DOMBRET H，SEYMOUR J F，BUTRYM A，et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30% blasts［J］.Blood，2015，126（3）：291-299.
［29］　FADER S，WETZLER M，RIZZIERI D，et al.Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia：results from the classic I trial［J］.J Clin Oncol，2016，30（20）：2492-2499.
［30］　MARTNEZ-CUADRN D，MONTESINOS P，ORIOL A，et al.Phase Ⅱ trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.［J］.Ann Hematol，2014，93（1）：43-46.
［31］　DENNIS M，RUSSELL N，HILLS R K，et al.A randomised assessment of vosaroxin and vosaroxin combined with low dose ara-C （LDAC） versus low dose ara-C alone in older patients with acute myeloid leukemia［J］.Blood，2015，125（19）：2923-2932.
［32］　FARHAD RAVANDI M D.Improved survival in patients with first relapsed or refractory acute myeloid leukemia（AML）treated with vosaroxin plus cytarabine versusplacebo plus cytarabine：results of a phase 3 double-blind randomized controlled multinational study（VALOR）［J］.Blood，2014，16（9）：1025-1036.
［33］　DAVER N,KANTARJIAN H M,GARCIA-MANERO G,et al.Abstract CT307:phase Ⅰ/Ⅱ study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)［J］.Cancer Res,2014,74(19 ):307-315.
［34］　WEI A H，TIONG I S.Midostaurin，enasidenib，CPX-351，gemtuzumab ozogomycin and venetoclax bring new hope to AML［J］.Blood，2017，130（23）：2469-2474.
［35］　ALEXANDRA R N，SHAMIT S，SOFIA A，et al.Human and murine hematopoietic stem cell aging is associated with functional impairments and intrinsic megakaryocytic/erythroid bias［J］.PLoS One，2016，11（7）：960-981.
［36］　刘娟，孙万军，赵红霞，等.“微移植”治疗80岁以上老年急性髓系白血病4例临床分析［J］.中国实验血液学杂志，2015，23（6）：1679-1683.

相似文献/References:

[1]张婧婧,张楠,王侠,等.急性髓系白血病四色流式细胞术免疫学分型特点分析[J].新乡医学院学报,2011,28(03):323.
[2]崔珊珊,李雅慧,赵晨瑾,等.二甲双胍对人急性髓系白血病KG1a细胞增殖和凋亡的影响及其机制[J].新乡医学院学报,2021,38(10):901.[doi:10.7683/xxyxyxb.2021.10.001]
　CUI Shanshan,LI Yahui,ZHAO Chenjin,et al.Effect and mechanism of metformin on proliferation and apoptosis of human acute myeloid leukemia KG1a cells[J].Journal of Xinxiang Medical University,2021,38(1):901.[doi:10.7683/xxyxyxb.2021.10.001]
[3]赵小强,吴雅莉,仝佳音,等.鱼藤素对急性髓系白血病KG-1a细胞增殖和凋亡的影响及机制[J].新乡医学院学报,2021,38(12):1121.[doi:10.7683/xxyxyxb.2021.12.003]
　ZHAO Xiaoqiang,WU Yali,TONG Jiayin,et al.Effect of deguelin on the proliferation and apoptosis of acute myeloid leukemia KG-1a cells and its mechanism[J].Journal of Xinxiang Medical University,2021,38(1):1121.[doi:10.7683/xxyxyxb.2021.12.003]
[4]张彦平,刘蒙蒙,展新荣.地西他滨联合小剂量高三尖杉酯碱和阿糖胞苷治疗老年急性髓系白血病疗效观察[J].新乡医学院学报,2020,37(11):1068.[doi:10.7683/xxyxyxb.2020.11.014]
　ZHANG Yanping,LIU Mengmeng,ZHAN Xinrong.Effect of decitabine combined with low-dose homoharringtonine and cytarabine in the treatment of elderly patients with acute myeloid leukemia[J].Journal of Xinxiang Medical University,2020,37(1):1068.[doi:10.7683/xxyxyxb.2020.11.014]
[5]张彦平,刘蒙蒙,展新荣.地西他滨联合三氧化二砷治疗老年急性髓系白血病的疗效及安全性[J].新乡医学院学报,2019,36(12):1163.[doi:10.7683/xxyxyxb.2019.12.015]
　ZHANG Yan-ping,LIU Meng-meng,ZHAN Xin-rong.Evaluation of the efficacy and safety of decitabine combined with arsenic trioxide in the treatment of senile acute myeloid leukemia[J].Journal of Xinxiang Medical University,2019,36(1):1163.[doi:10.7683/xxyxyxb.2019.12.015]
[6]王继芳,魏秀丽.氟达拉滨联合阿糖胞苷治疗急性髓系白血病疗效观察[J].新乡医学院学报,2018,35(3):204.[doi:10.7683/xxyxyxb.2018.03.011]
　WANG Ji-fang,WEI Xiu-li.Effect of fludarabine combined with cytarabine on acute myeloid leukemia[J].Journal of Xinxiang Medical University,2018,35(1):204.[doi:10.7683/xxyxyxb.2018.03.011]
[7]尹俊杰,梁　波,王继芳,等.阿柔比星为基础的联合化学治疗方案治疗成人初治急性髓系白血病疗效观察[J].新乡医学院学报,2017,34(1):072.[doi:10.7683/xxyxyxb.2017.01.021]
　YIN Jun-jie,LIANG Bo,WANG Ji-fang,et al.Efficacy of aclarubicin-based chemotherapy induction regimens for adult de-novo acute myeloid leukemia[J].Journal of Xinxiang Medical University,2017,34(1):072.[doi:10.7683/xxyxyxb.2017.01.021]
[8]孟君霞,武永强,唐　广,等.CD7抗原表达与急性髓系白血病临床特征、细胞遗传学特点及预后的关系[J].新乡医学院学报,2016,33(6):508.[doi:10.7683/xxyxyxb.2016.06.017]
　MENG Jun-xia,WU Yong-qiang,TANG Guang,et al.Relationship between CD7 antigen expression and clinical features，cytogenetic features，prognosis of acute myeloid leukemia[J].Journal of Xinxiang Medical University,2016,33(1):508.[doi:10.7683/xxyxyxb.2016.06.017]
[9]张雪莹,李晓芳,张红伟,等.地氟烷与七氟烷吸入麻醉对行全身麻醉下腹部手术老年患者苏醒质量及认知功能的影响比较[J].新乡医学院学报,2022,39(8):726.[doi:10.7683/xxyxyxb.2022.08.005]
　ZHANG Xueying,LI Xiaofang,ZHANG Hongwei,et al.Comparison of effects of desflurane and sevoflurane inhalation anesthesia on recovery quality and cognitive function of elderly patients undergoing abdominal surgery under general anesthesia[J].Journal of Xinxiang Medical University,2022,39(1):726.[doi:10.7683/xxyxyxb.2022.08.005]
[10]张晓冬,林晓媛.急性髓系白血病患者外周血调节性T细胞、辅助性T细胞17及其相关细胞因子的表达及意义[J].新乡医学院学报,2023,40(4):339.[doi:10.7683/xxyxyxb.2023.04.008]
　ZHANG Xiaodong,LIN Xiaoyuan.Expression and significance of regulatory T cells,helper T cell 17 cells and their related cytokines in peripheral blood of patients with acute myeloid leukemia[J].Journal of Xinxiang Medical University,2023,40(1):339.[doi:10.7683/xxyxyxb.2023.04.008]

更新日期/Last Update: 2019-01-05